Quantitative immunohistochemical analysis of myeloid cell marker expression in human cortex captures microglia heterogeneity with anatomical context

Molly E. V. Swanson1,2, Helen C. Murray1,2, Brigid Ryan1,2, Richard L. M. Faul1,2, Mike Dragunow2,3 & Maurice A. Curtis1,2*

Current immunohistochemical methods of studying microglia in the post-mortem human brain do not capture the heterogeneity of microglial function in response to damage and disease. We therefore investigated the expression of eight myeloid cell proteins associated with changes in function alongside Iba1. To study the myeloid cells we used immunohistochemistry on post-mortem human middle temporal gyrus sections from neurologically normal individuals. First we investigated co-labelling between the classical ‘activation’ marker, HLA-DR and each of the other markers of interest. Significant co-labelling between HLA-DR with CD206, CD32, CD163, or L-Ferritin was observed, although complete overlap of expression of HLA-DR with aforementioned markers was not observed. A qualitative assessment also demonstrated that perivascular macrophages expressed higher levels of the markers of interest we investigated than microglia, suggesting perivascular macrophages show a more phagocytic and antigen presentation state in the human brain. To determine whether the markers of interest were expressed in different functional states, the immunoreactivity for each marker was qualitatively assessed on microglial morphologies. Degenerating marker, L-Ferritin, was specific for dystrophic microglia. We demonstrate that microglial heterogeneity can be investigated in immunohistochemically stain post-mortem human tissue by integrating the single-cell abundance of proteins and cell morphology to infer function.

Abbreviations

CD  Cluster of differentiation
CNS  Central nervous system
GM  Grey matter
HLA-DR  Human leukocyte antigen, DR isotype
Iba1  Ionised calcium binding adaptor protein 1
MOI  Marker of interest
PI  Point intensity
PMD  Post-mortem delay
PVM  Perivascular macrophage
TSA  Tyramide signal amplification
UEA-1  Ulex europaeus-1
WM  White matter

1Department of Anatomy and Medical Imaging, Faculty of Medical and Health Science, University of Auckland, Private Bag 92019, Auckland, New Zealand. 2Centre for Brain Research, Faculty of Medical and Health Science, University of Auckland, Private Bag 92019, Auckland, New Zealand. 3Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Science, University of Auckland, Private Bag 92019, Auckland, New Zealand. *email: m.curtis@auckland.ac.nz
Microglia are the innate immune cells of the brain capable of responding to damage and disease. Because of the high abundance of stimuli in vivo, the variety of microglial reactions in the normal and diseased human brain make this population highly heterogeneous. Historically, these microglial reactions during damage and/or disease have been considered ‘activation’. However, this on/off terminology is being phased out as it does not reflect microglial heterogeneity. We sought to investigate how the heterogeneity of microglial and perivascular macrophage reactions can be investigated in post-mortem human tissue, as well as the single-cell abundance of key proteins of interest and cell morphology to infer function. We investigated seven myeloid cell proteins in this study: P2RY12, TMEM119, CD74, CD206, CD32, CD163, and L-Ferritin. These proteins were chosen because they have previously been highlighted by single cell RNA sequencing studies, investigated in post-mortem human brain studies, we could demonstrate antibody specificity in human brain, or show a unique expression by microglia or perivascular macrophages (Supplementary Table 1). We investigated the expression of these myeloid cell proteins in the human brain by co-labelling them with the classical immunohistochemical ‘activation’ marker, human leukocyte antigen-DR isotype (HLA-DR), investigating their expression on microglia and perivascular macrophages, and identifying their expression on microglia with different morphologies.

One of the most common immunohistochemical markers used to identify and quantify so-called microglial activation in the normal and diseased post-mortem human brain is HLA-DR. HLA-DR is an antigen presentation molecule involved in the activation of the adaptive immune system. This function, along with high HLA-DR immunoreactivity being identified surrounding amyloid beta plaques in human Alzheimer’s disease brains, resulted in HLA-DR being classed as a marker of pan microglial ‘activation’ in immunohistochemistry studies. This presents challenges when considering the heterogeneity of microglial reactions to damage and disease. Furthermore, HLA-DR is constitutively expressed by some resting microglia in the human brain and there is no evidence that HLA-DR is up-regulated through all forms of microglial reactions. HLA-DR is only one of thousands of proteins that are differentially up-regulated during a microglial reaction to damage and/or disease and reflects only one function. We hypothesise that using multiple markers which reflect different myeloid cell functions will better capture the heterogeneity of microglial functions in studies of post-mortem human tissue. We quantified the co-labelling between each marker and HLA-DR to determine whether we could identify different microglial populations in the post-mortem human brain that likely had different functions in the brain. Determining the expression of this subset of proteins relative to the classical immunohistochemical activation marker allowed us to determine whether they are expressed by unique populations of myeloid cells that do not express HLA-DR.

To determine whether the markers of interest (MOIs) are upregulated on microglia that have diverse morphologies, we assessed MOI expression on the common microglial morphologies as a proxy for particular microglial functions. Morphological changes occur during microglial responses to damage and/or disease, and are hypothesised to increase functions to maintain brain homeostasis. Five distinct microglial morphologies are readily identifiable: ramified, hypertrophic, dystrophic, rod, and amoeboid. In previous studies of post-mortem human brain tissue, microglial morphologies have been used to infer activation state and function. However, it is important to note that microglial functions are not specific to a given morphology, but rather that morphologies can imply an increase in given functions. We investigated protein expression on different microglial morphologies to determine their expression throughout different microglial states indicative of different functions.

One consideration of this study was that microglia are not the only myeloid cells in the human brain that express the proteins being investigated. Perivascular macrophages (PVMs) are one border-associated macrophage population that reside in the perivascular space of the blood brain barrier. While microglia and PVMs are both resident myeloid populations in the human CNS, they occupy different central nervous system compartments and are therefore different functional populations. Because the hypothesis of this study was that the proteins investigated can be used as markers of microglial activation and function in the brain, the expression pattern of these proteins on microglia and PVMs was examined.

| Marker | Microglia | Perivascular Macrophage |
|--------|----------|-------------------------|
| P2RY12 | +++      | −                       |
| TMEM119| +++      | −                       |
| HLA-DR | ++       | +++                     |
| CD74   | +++      | +++                     |
| CD206  | −        | +++                     |
| CD32   | ++       | +++                     |
| CD163  | +        | ++                      |
| L-Ferritin | ++ | −                       |

Table 1. Semi-quantitative summary of marker abundance on myeloid cell populations. Key: (−) not observed, (+) low abundance, (+ +) moderate abundance, or (+ + +) high abundance in the myeloid cell population.
with HLA-DR in neurologically normal aged brains which establishes important context for subsequent studies of neurological disease.

Results

Markers of interest are differentially expressed in grey versus white matter across the Iba1-positive population. The immunoreactivity of the MOIs indicative of function were first assessed on Iba1-positive myeloid cells in the middle temporal gyrus grey matter (GM) and white matter (WM) from neurologically normal subjects. Immunoreactivity for P2RY12, TMEM119, HLA-DR, CD74, CD206, CD32, CD163, and L-Ferritin was observed on Iba1-positive cells (Fig. 1).

To investigate the expression of the MOIs within the myeloid cell population we used manual cell counting to determine the percentage of total Iba1-positive cells that were immunoreactive for each MOI. We carried out this quantification in both the GM and WM as previous research has not investigated the potential differences in the MOI expression between these regions. It is important to note that we deemed it appropriate to compare the abundance of MOIs normalised to the total number of Iba1-positive cells for this study because we did not identify any difference in Iba1-positive cell density between GM and WM (mean WM-GM difference = 17.16 ± 20.88 cells/mm², p = 0.1001).

P2RY12 and CD74 were the most abundant markers in the Iba1-positive population and were equally distributed between GM and WM (Fig. 2). The two least abundant markers were CD206 and CD163, which were more highly expressed by Iba1-positive cells in GM than WM (Fig. 2). CD32 and L-Ferritin, were also more highly expressed by Iba1-positive cells in the GM than WM (Fig. 2). TMEM119 and HLA-DR, were expressed equally by Iba1-positive cells in the GM and WM (Fig. 2). The abundance of the MOIs in the Iba1-positive population did not correlate with age or post-mortem delay (Supplementary Fig. 2).

Markers of interest are expressed by HLA-DR-positive Iba1-positive cells, but the cell-by-cell intensity of each marker does not strongly correlate with HLA-DR intensity. Quantification of the MOIs on Iba1-positive cells demonstrated that the percentage of Iba1-positive cells that expressed these proteins differed depending on the MOI. We hypothesised that this was because at least some of the MOIs were up-regulated by microglia with different predominant functions during reactions. We hypothesised that these MOIs could be expressed by functional populations not expressing HLA-DR. To test this hypothesis, we carried out a co-labelling analysis with HLA-DR. Only the GM was used for this aspect of the study and all Iba1-positive cells within the image were manually counted.

All the MOIs we studied co-labelled with HLA-DR (Fig. 3). To determine whether there was a relationship between HLA-DR and MOI expression, we investigated the correlation between the point intensities of HLA-DR and each MOI on all Iba1-positive cells (Fig. 4). No linear correlations between HLA-DR point intensities and TMEM119 or P2RY12 point intensities were observed on Iba1-positive cells (Fig. 4A, B). Only moderate correlations between HLA-DR point intensities and the remaining MOI point intensities were observed (Fig. 4C–G). Of these correlations, we further analysed the cells with HLA-DR or MOI point intensities in the top ten percent of values to determine whether the Iba1-positive cells that are potentially the most reactive are up-regulating multiple proteins and respective functions. When the top ten percent of HLA-DR point intensities were analysed, we did not observe any stronger correlations with the MOI point intensities (Supplementary Fig. 3). Furthermore, when the top ten percent of MOI point intensities were analysed, no stronger correlations with HLA-DR point intensities were observed (Supplementary Fig. 3). Therefore, the Iba1-positive cells that highly express HLA-DR do not highly express other MOIs indicative of other microglial functions.

Categorisation of HLA-DR and MOI populations shows functional markers are more abundant on HLA-DRhigh than on HLA-DRlow Iba1-positive cells. Some moderate linear correlations were observed in the overall correlations of HLA-DR with MOI point intensities on Iba1-positive cells. However, the highest ten percent of HLA-DR or MOI point intensity correlations demonstrated that high HLA-DR and high MOI expression did not always co-occur. This result may have simply been an artefact of HLA-DR and MOI point intensity variability across Iba1-positive cell bodies. To test this, we carried out a second analysis whereby we categorised Iba1-positive cells as HLA-DRhigh and MOIhigh, resulting in four populations; HLA-DRhigh MOIhigh, HLA-DRhigh MOIlow, HLA-DRlow MOIhigh, and HLA-DRlow MOIlow. Chi-square analyses were used on the pooled Iba1-positive populations from all six normal cases to determine whether there was a relationship between the cellular abundance of HLA-DR and the MOIs (Fig. 5A–G). The percentage of MOIhigh cells within the HLA-DRhigh versus the HLA-DRlow populations was analysed to determine whether HLA-DRhigh cells had a higher abundance of the MOI (Fig. 5H–N). Conversely, the percentage of HLA-DRhigh cells within the MOIhigh versus the MOIlow populations was analysed to determine whether the MOIhigh population had a higher abundance of HLA-DR (Fig. 5O–U). This categorial analysis allowed us to determine whether the MOIs investigated in this study are highly expressed by Iba1-positive cells not expressing HLA-DR.

In accordance with the lack of linear correlations identified, a Chi-square analysis on the pooled Iba1-positive HLA-DR-P2RY12 and HLA-DR-TMEM119 populations showed no relationship between HLA-DR and the expression of P2RY12 or TMEM119 (Fig. 5A, B). Furthermore, when the populations were grouped by HLA-DRhigh, the percentage of the HLA-DRhigh population identified as P2RY12high or TMEM119high was not statistically different from the percentage of the HLA-DRlow population that was P2RY12high or TMEM119high (Fig. 5H, I). The same result was observed when the populations were grouped by P2RY12high or TMEM119high and the percentage of these populations that were HLA-DRhigh were compared (Fig. 5O, P). Therefore, neither microglial-specific marker is more abundant on HLA-DRhigh Iba1-positive cells than on HLA-DRlow Iba1-positive cells.
Figure 1. Marker of interest expression by Iba1-positive cells. MOIs, P2RY12 (A), TMEM119 (B), HLA-DR (C), CD74 (D), CD206 (E), CD32 (F), CD163 (G), and L-Ferritin (H), were fluorescently co-labelled with pan myeloid cell marker, Iba1, and Hoechst nuclear counterstain in 50-µm thick normal human middle temporal gyrus sections. Images are maximum projections of confocal z-stacks; scale bars = 20 µm. Arrows indicate Iba1-positive cell bodies with marker of interest immunoreactivity.
Chi-square analysis on the pooled Iba1-positive HLA-DR-CD74 population demonstrated a relationship between HLA-DR and CD74 expression (Fig. 5C). When the HLA-DR-CD74 populations was grouped by HLA-DRhigh/low, we found that the percentage of the HLA-DRhigh population that was CD74high was significantly higher than the percentage of the HLA-DRlow population that was CD74low (Fig. 5I). In contrast with this, when the HLA-DR-CD74 populations were grouped by CD74high/low, the percentage of the CD74high population that was also HLA-DRhigh was not significantly different to the percentage of the CD74low population that was HLA-DRlow (Fig. 5Q). Therefore, while CD74 was more abundant in the HLA-DRhigh population, HLA-DR was equally abundant in the CD74high and CD74low populations.

Because of the high expression of P2RY12, TMEM119, and CD74 across the entire Iba1-positive population and the unremarkable pattern of co-labelling with HLA-DR, these three MOIs are unlikely to reflect unique functional populations of reactive microglia in post-mortem human brain.

Chi-square analyses on the remaining pooled Iba1-positive HLA-DR-MOI populations demonstrated relationships between HLA-DR and the remaining MOIs (Fig. 5D–G). When the populations were grouped by HLA-DRhigh/low, we found that the percentage of the HLA-DRhigh population that was MOIlow was significantly higher than the percentage of the HLA-DRlow population that was MOIlow (Fig. 5J–N). Therefore, these five MOIs were more abundant in the HLA-DRhigh than the HLA-DRlow population. For the remaining MOIs, when the populations were grouped by MOIlow/high, the percentage of the MOIlow population identified as HLA-DRhigh was significantly higher than the percentage of the MOIlow that were HLA-DRhigh (Fig. 5R–U). Therefore, we identified significant co-labelling between HLA-DR and CD206, CD32, CD163, or L-Ferritin in post-mortem human brain tissue. It is important to note that for all of these MOIs, we also identified HLA-DRhigh MOIlow and HLA-DRlow MOIlow populations. So while HLA-DRhigh Iba1-positive cells are more likely to also be MOIlow than HLA-DRlow Iba1-positive cells, some Iba1-positive cells uniquely express HLA-DR or a MOI highly.

Markers of interest are differentially expressed by microglia and perivascular macrophages in the normal human middle temporal gyrus. Our results so far have not distinguished between the different types of myeloid cells that express Iba1 in the human brain. Within the middle temporal gyrus grey matter, we would expect to encounter both Iba1-positive microglia and PVMs. The majority of microglia are not associated with blood vessels and they are therefore typically easily distinguishable from PVMs. However, a subset of microglia (juxtavascular microglia) are located alongside blood vessels and are therefore indistinguishable from PVMs by location alone. To overcome this issue, Iba1-positive cells were classified as microglia or PVMs based on their cellular morphology and location relative to lectin-positive blood vessels. Microglia were identified as Iba1-positive cells with a highly ramified morphology which could be juxtavascular i.e. associated with lectin-positive blood vessels (Fig. 6A), as well as scattered throughout the brain parenchyma. In contrast, PVMs were identified as Iba1-positive cells with an elongated cell body adjacent to lectin-positive blood vessels (Fig. 6B).

Using this method to identify microglia and PVMs, we investigated the marker of interest immunoreactivities on these CNS myeloid cells (Table 1). Based on the semi-quantitative assessment of the population wide expression, seven of eight MOIs investigated were differentially expressed by microglia versus PVMs. P2RY12, TMEM119, and L-Ferritin were only observed on microglia. Conversely, CD206 was only observed on PVMs. HLA-DR, M CD32, and CD163 were expressed by both microglia and PVMs but were more highly expressed by PVMs than microglia. CD74 was the only marker to be equally expressed by both myeloid populations.
Figure 3. Immunofluorescent co-labelling of markers of interest with HLA-DR on Iba1-positive cells. MOIs, P2RY12 (A), TMEM119 (B), CD74 (C), CD206 (D), CD32 (E), CD163 (F), and L-Ferritin (G), were fluorescently co-labelled with HLA-DR, pan myeloid cell marker, Iba1, and Hoechst nuclear counterstain in 50-µm thick normal human middle temporal gyrus sections. Images are maximum projections of confocal z-stacks; scale bars = 20 µm.
Marker of interest expression varies across microglial morphologies. The identification of high, but not total, co-occurrence of HLA-DR$^{\text{high}}$ and MOI$^{\text{high}}$ expression in the case of CD32, CD163, and L-Ferritin led to the hypothesis that each of these MOI are more up-regulated during different microglial reactions than HLA-DR. We hypothesise that high expression of HLA-DR or the MOIs investigated in this study are indicative of an increase in a distinct function during microglial reactions. One way of assessing microglial reactions in post-mortem human tissue is through the analysis of microglial morphologies. Therefore, to investigate this
hypothesis, we qualitatively assessed the expression of HLA-DR and MOI across different microglial morphologies.

Five Iba1-positive cell morphologies were identified in the normal human brain (Fig. 7). Ramified had small triangular cell bodies with thin, highly branched processes (Fig. 7A). Hypertrophic reactive microglia had larger cell bodies with more intense Iba1 immunoreactivity, thickened processes, and were typically bipolar (Fig. 7B). Dystrophic microglia are the damaged or dying microglia and were identified by de-ramification of processes, membrane fragmentation, and had small, rounded or irregularly shaped nuclei (Fig. 7C). Rod microglia are hypothesised to be the supportive morphology, believed to form along neuronal axons in the grey matter to support signalling. These were identifiable as bipolar microglia with thin, branching processes that lay parallel to neuronal axons projecting through cortical layers (Fig. 7D). Amoeboid microglia can functionally traverse through tissue and readily phagocytose large debris. Morphologically, they have no processes or in some cases, have a small leading process. In this study, they were most readily identified as cells with Iba1 immunoreactivity in a layer around the nucleus (Fig. 7E).

Following the identification of Iba1-positive cell morphologies, the expression of MOIs was investigated across microglial morphologies. It is important to note that amoeboid microglia were not included in this study because, (1) amoeboid microglia and macrophages in the brain parenchyma (whether they are due to infiltration before death or a post-mortem artefact) are difficult to distinguish; and (2) amoeboid microglia are not abundant in the neurologically normal aged human brain and it was unlikely that a representative amoeboid microglia sample could be obtained from the sections stained. Furthermore, CD206 was not included in this analysis due to its immunoreactivity being confined to PVMs.

P2RY12, TEMEM119, HLA-DR, and CD74 were expressed across all four morphologies investigated. CD32 was expressed on pure ramified, hypertrophic, and dystrophic morphologies. It was expressed by microglia that were bipolar and displayed correct cortical orientation characteristic of rod microglia, but these CD32 immunoreactive cells also showed signs of hypertrophy. Similarly, CD163, was only expressed on ramified, hypertrophic, and dystrophic microglia. Finally, L-Ferritin, was observed on purely dystrophic microglia. Any ramified or hypertrophic microglia that expressed L-Ferritin appeared to have a mixed morphology whereby they also showed signs of dystrophy. Furthermore, no rod microglia showed L-Ferritin immunoreactivity. These results are summarised in Table 2.

Discussion
This study has provided a comprehensive characterization of HLA-DR co-labelling with seven other myeloid cell proteins that contribute to microglial reactions in vivo. Using single cell immunohistochemical quantification methods, we have shown that these proteins identify additional reactive microglial populations to that of HLA-DR alone in post-mortem cortex from neurologically normal aged controls. Our results therefore reinforce the conclusion from single-cell RNA sequencing studies that microglial heterogeneity is extensive. As such, we propose that anatomical studies of microglial changes in disease context using post-mortem human tissue should use this wider panel of markers in conjunction with HLA-DR.

Current immunohistochemical methods of studying microglia in the post-mortem human brain do not capture the heterogeneity of microglial function changes in response to damage and disease. Even in recent studies, HLA-DR is the standard and often lone marker used to identify microglial reactivity. Analysis of microglia in post-mortem tissue is also complicated by using methods that quantify the immunoreactivity across an area of tissue and therefore miss the subtlety of changes that occur at the single cell level. We therefore undertook an immunohistochemical analysis of seven markers whose expression by Iba1-positive cells can be used to infer a wider range of cell functions in the post-mortem human cortex. We also developed and validated a single cell quantification method to assess the correlation of marker intensity with HLA-DR intensity. Our results indicate that this combined approach of single cell immunohistochemical analysis using a range of markers provides a more comprehensive assessment of microglial heterogeneity in post-mortem tissue with anatomical context. This is evidenced by our assessment of grey and white matter where we show the diverse expression of these proteins across these two compartments, supporting the findings of previous single-cell RNA sequencing studies. Studies of post-mortem tissue are inherently limited in that they reflect a single time point at the end of life and stage of disease. This makes it difficult to study dynamic processes such as microglial reactions. While single-cell RNA sequencing studies in human tissue have provided evidence of distinct microglial populations with unique
expression signatures, these findings remain to be validated anatomically using immunohistochemistry. Our approach provides an effective means to capture this spectrum of microglial function changes with anatomical context and assess new microglial markers in future studies.

Our study investigated proteins that can be used to distinguish microglia and PVMs (TMEM119, P2RY12, CD206) or infer an increase in different myeloid cell functions such as antigen presentation (HLA-DR, CD74), phagocytosis (CD32, CD163) or degeneration (L-ferritin). These protein markers have previously been used in studies of human brain tissue and provided a reliable basis to investigate microglial reaction heterogeneity in relation to HLA-DR expression using our quantification method. We identified that all seven of these proteins or MOIs are expressed by HLA-DR-positive myeloid cells (determined by Iba1), but the cell-by-cell intensity of each marker does not strongly correlate with HLA-DR intensity. Categorisation into high vs low HLA-DR and MOI populations shows functional markers are more abundant on HLA-DRhigh Iba1-positive cells. Therefore, our data suggest that these myeloid cell proteins are significantly co-expressed with HLA-DR on Iba1-positive cells and that the HLA-DR population encompasses a broad range of microglial reactions. However, we also identified both HLA-DRhigh MOIlow and HLA-DRlow MOIhigh Iba1-positive populations. This finding suggests that HLA-DR and each of the MOIs also label different functional populations of Iba1-positive cells in immunohistochemically stained post-mortem tissue. This finding is consistent with extensive microglial heterogeneity observed in single cell RNA sequencing studies and indicates there is considerable heterogeneity even within the HLA-DR population4,7,48–50.

To further corroborate the functional changes that are implied by increased expression of the myeloid cell proteins, we investigated the expression of the MOIs on microglial morphologies. Different microglial morphologies can be identified in immunohistochemically stained post-mortem human tissue and are hypothesised to reflect the predominant function of a given microglia33,38,51. An important limitation is that morphological changes are highly dynamic, and it is extremely difficult to define the morphology of cells that may be in transition between different states. Therefore, quantitative assessment of morphologies is highly subjective. Studies have attempted to overcome this subjectivity by developing unbiased computational analysis methods. Cell body size, number of processes, and process volume have been used to classify microglia into ramified, hypertrophic, dystrophic and amoeboid morphologies52,53. However, as no defined set of morphological criteria exist, quantification of these classifications is still highly subjective to user defined parameters54. While qualitative assessment of morphologies does not account for cells in transitional states, it is possible to identify the cells at the extreme ends of the transitional spectrum as distinct morphologies. We used this approach to identify whether our markers showed specificity to any distinct morphologies.

The majority of the MOIs investigated did not show specificity to a single morphology, indicating that their functional associations are not necessarily indicative of a specific morphological shift. This result indicates that heterogeneity in microglial reactions encompasses morphological diversity as well as protein expression. However, L-Ferritin immunoreactivity in the human brain was specific to dystrophic microglia. While the shift from ramified ‘resting’ morphology to a hypertrophic morphology is associated with microglial reactions, dystrophic...
Figure 7. Indication of the five Iba1-positive microglial morphologies in the human brain. Microglia expressing pan marker, Iba1 (green), with a ramified (A), hypertrophic (B), rod (C), dystrophic (D) and amoeboid (E) morphology present in the human middle temporal gyrus. Main cell bodies with Hoechst-positive nuclei (blue) are indicated with block white arrows while morphology characteristics are indicated with small white arrow outlines. Images are maximum projections of confocal z-stacks; scale bars = 10 μm.
morphology is thought to reflect senescence and degeneration. The accumulation of dystrophic L-Ferritin\textsuperscript{high} microglia in the AD brain is hypothesised to be a result of disrupted iron homeostasis, which is also disrupted in the normal ageing brain. Thus, the L-ferritin\textsuperscript{high} population we identified likely reflects age-related processes. L-Ferritin point intensities moderately correlated with HLA-DR point intensities on Iba1-positive cells and the Chi-square analysis demonstrated that L-Ferritin was more abundant on HLA-DR\textsuperscript{high} cells than HLA-DR\textsuperscript{low} cells. This suggests that the HLA-DR microglial population includes degenerating microglia and together our results support those of previous studies indicating that L-ferritin and dystrophic morphology can reliably distinguish this population of senescent or degenerating microglia in human tissue.

As our study investigated the expression of myeloid cell proteins on Iba1-positive cells, our analysis included both PVMs and microglia. To determine the expression of each MOI across these two myeloid cell populations, and therefore the potential contribution of the PVMs to our results, we carried out a qualitative assessment to determine MOI expression across microglia and PVMs. We found that HLA-DR, CD206, CD32, and CD163 were more abundant on PVMs than microglia. These protein expression patterns have been observed previously, where CD206 and CD163 have been described as positive discriminators of PVMs\textsuperscript{16,20,21,56,57}. We identified CD163 immunoreactivity on ramified Iba1-positive microglia which, in parallel with previous studies, demonstrates that microglia are also capable of up-regulating CD163, just to a lesser extent than PVMs\textsuperscript{20–24}. The three MOIs that were more highly expressed by PVMs than microglia (CD206, CD32, CD163) have roles in antigen presentation and phagocytosis\textsuperscript{15,18,22,30,58}. The expression patterns observed in this study therefore suggest that in the normal human brain PVMs show greater antigen presentation and phagocytic capabilities than microglia.

Protein expression by microglia and PVMs is driven by microenvironmental stimuli. It is therefore hypothesised that the different protein expression profiles of PVMs and microglia are a result of them populating different CNS compartments\textsuperscript{13}. The borders between the brain and the periphery restrict the influx of potentially harmful peripheral components into the brain parenchyma, thus helping to maintain homeostasis\textsuperscript{16,20,43–46}. In normal conditions, parenchymal microglia would have reduced environmental stimuli driving MOI protein expression. In contrast, PVMs function on the border of the brain and peripheral blood stream, surveying the influx of peripheral components into the CNS from the blood\textsuperscript{39,60}. PVMs are therefore subjected to a range of environmental stimuli and their protein expression is directly influenced by changes in the periphery. PVMs are key border phagocytes with antigen presentation capabilities that regulate immune responses, and all these functions involve the up-regulation of proteins like those investigated\textsuperscript{14,15,20–24,40–42}. While the work presented here is not primarily focused on PVM activation, the differences in MOI expression between microglia and PVMs do highlight that these difference cell types contribute to the overall myeloid cell heterogeneity that we wish to study in post-mortem tissue in a disease context in future studies.

| Marker of Interest | Ramified | Hypertrophic | Dystrophic | Rod |
|-------------------|----------|--------------|------------|-----|
| P2RY12            | ✓        | ✓            | ✓          | ✓   |
| TMEM119           | ✓        | ✓            | ✓          | ✓   |
| HLA-DR            | ✓        | ✓            | ✓          | ✓   |
| CD74              | ✓        | ✓            | ✓          | ✓   |
| CD32              | ✓        | ✓            | ✓          | ✓   |
| CD163             | ✓        | ✓            | ✓          | ✓   |
| L-Ferritin        | ✓        | ✓            | ✓          | ×   |

Table 2. Immunoreactivity of markers of interest on microglial morphologies. Key: (×) not observed, (✓) observed, (✓*) observed on mixed morphologies.

| Fixation            | Case number | Hemisphere | Age | Sex  | Post-mortem Delay (h) |
|---------------------|-------------|------------|-----|------|-----------------------|
| Formalin-fixed frozen | H169         | Right      | 81  | Male | 24                    |
|                     | H187         | Left       | 98  | Female | 15                   |
|                     | H196         | Left       | 85  | Male  | 15                    |
|                     | H241         | Right      | 76  | Female | 12                    |
|                     | H243         | Right      | 77  | Female | 13                    |
| Paraffin-embedded   | H229         | Right      | 88  | Female | 17                    |
|                     | H230         | Right      | 57  | Female | 32                    |
|                     | H240         | Right      | 73  | Male  | 27                    |
|                     | H242         | Right      | 61  | Male  | 20                    |
|                     | H244         | Right      | 76  | Male  | 16                    |
|                     | H246         | Right      | 89  | Male  | 17                    |

Table 3. Human cases used for this study.
fin embedding as previously described. For the quantitative co-labelling analysis of each MOI with HLA-DR, morphologies were assessed of MOI abundance on microglia and PVMs, and the assessment of MOI abundance on Iba1-positive cells, qualitative co-labelling of each MOI with HLA-DR, the identification and qualitative assessment of MOI expression containing 0.1% sodium azide. These free-floating sections were used for the identification of MOI expression marker of endothelial cells. Two forms of lectin from Ulex europaeus-1 were used for the visualisation of blood vessels as it is a specific marker of endothelial cells. Concentration Visualisation

| Primary antibody | Company, Catalogue number | Free-floating Immunohistochemistry | Paraffin Immunohistochemistry |
|------------------|---------------------------|----------------------------------|-------------------------------|
| goat anti-Iba1   | Abcam, ab5076             | 1:2,000                          | Alexa Fluor 647 secondary     |
| rabbit anti-P2RY12 | Sigma Aldrich, HFA014518   | 1:2,000                          | Alexa Fluor 488 secondary     |
| rabbit anti-TMEM119 | Abcam, ab185333            | 1:500                            | TSA Alexa Fluor 488           |
| mouse anti-HLA-DR | DAKO, M0775               | 1:1,000                          | Alexa Fluor 488 or 594 secondary |
| rabbit anti-CD74  | Abcam, ab64772            | 1:500                            | Alexa Fluor 488 secondary     |
| rabbit anti-CD206 | Abcam, ab64693            | 1:1,000                          | Alexa Fluor 488 secondary     |
| rabbit anti-CD32  | Abcam, ab155972           | 1:500                            | TSA Alexa Fluor 488           |
| rabbit anti-CD163 | Abcam, ab182422           | 1:1,000                          | TSA Alexa Fluor 488           |
| rabbit anti-L-Ferritin | Sigma Aldrich, F5012      | 1:2,000                          | Alexa Fluor 488 secondary     |

Table 4. Primary antibodies, concentrations, and visualisation methods for this study.

We have presented evidence that single cell immunohistochemical analysis of seven different myeloid cell proteins can be used to identify unique functional populations that are not distinguished by HLA-DR alone. We show that these proteins are significantly associated with HLA-DR, but also label Iba1-positive cells without HLA-DR expression. Furthermore, these markers are expressed by microglia that show a range of morphologies which emphasizes that both protein expression and morphology reflect overall microglial heterogeneity. We also identified that these proteins are differentially expressed by microglia and PVMs in the human brain. Our results provide a baseline for the co-labelling of these markers with HLA-DR in neurologically normal aged brains which establishes important context for subsequent studies of neurological disease.

Methods

Human tissue processing. Post-mortem human brain tissue was obtained from the Neurological Foundation Human Brain Bank at the University of Auckland Centre for Brain Research. The human tissue was donated to the Brain Bank with consent from the donors' families and its use in this project was approved by the University of Auckland Human Participants Ethics Committee. Eleven normal cases were used for this study (Table 3; average age = 78.27 ± 12.01 years, range = 61–98 years; average post-mortem delay = 18.91 ± 6.268 h, range = 12–32 h; 5 female:6 male). All normal cases had no history of cognitive deficits and their cause of death was unrelated to any neurological condition. The normal cases had age-related pathological changes, relating to a maximum Braak score of II or maximum CERAD score of A3B0C0 or equivalent, as determined by an independent pathological analysis.

Human brains were obtained at autopsy and the right, and on occasion the left, hemisphere was fixed by perfusion of formalin through the cerebral arteries and subsequently dissected into blocks, cryoprotected, and frozen as previously described. Coronal Sects. (50- or 100-µm thick) of fixed-frozen middle temporal gyrus sections were cut from paraffin-embedded blocks from the normal cases indicated in Table 3 using a freezing sliding microtome and stored at 4°C in PBS containing 0.1% sodium azide. These free-floating sections were used for the identification of MOI expression on Iba1-positive cells, qualitative co-labelling of each MOI with HLA-DR, the identification and qualitative assessment of MOI abundance on microglia and PVMs, and the assessment of MOI abundance on microglial morphologies.

Dissection of the formalin-fixed hemisphere, 1-cm thick blocks were taken and processed for paraffin embedding as previously described. For the quantitative co-labelling analysis of each MOI with HLA-DR, 10-µm thick sections were cut from paraffin-embedded middle temporal gyrus blocks from the normal cases indicated in Table 3 using a rotary microtome.

Fluorescent immunohistochemical staining of Iba1 and markers of interest. For qualitative MOI assessments, free-floating fluorescent immunohistochemistry was carried out on the 50- and 100-µm thick middle temporal gyrus sections as previously described. In short, sections were placed into tris–EDTA pH 9.0 buffer and microwaved at 1,100 W for 30 s or until the solution boiled. The sections were incubated in the solution containing primary antibodies for 72 h at 4°C on a rocking platform (Table 4) and then in a solution containing fluorophore-conjugated secondary antibody, specific to the primary antibody species, overnight at room temperature. Lastly, sections were incubated in Hoechst (1:20,000 in PBS, Molecular Probes, #33,342) mounted onto glass slides and coverslipped.

Lectin from Ulex europaeus-1 (UEA-1) was used for the visualisation of blood vessels as it is a specific marker of endothelial cells. Two forms of lectin from UEA-1 were used in conjunction with other primary antibodies to label blood vessels in the free-floating MTG sections. A biotinylated lectin from UEA-1 (1:1,000, Sigma-Aldrich, L8262) was visualised using an AlexaFluor 647-conjugated Streptavidin (1:500, Sigma-Aldrich, Cat. #709360). Primary antibody

Concentration Visualisation

| Primary antibody | Company, Catalogue number | Concentration | Visualisation |
|------------------|---------------------------|---------------|---------------|
| goat anti-Iba1   | Abcam, ab5076             | 1:2,000       | Alexa Fluor 647 secondary |
| rabbit anti-P2RY12 | Sigma Aldrich, HFA014518   | 1:2,000       | Alexa Fluor 488 secondary |
| rabbit anti-TMEM119 | Abcam, ab185333            | 1:500         | TSA Alexa Fluor 488     |
| mouse anti-HLA-DR | DAKO, M0775               | 1:1,000       | Alexa Fluor 488 or 594 secondary |
| rabbit anti-CD74  | Abcam, ab64772            | 1:500         | Alexa Fluor 488 secondary |
| rabbit anti-CD206 | Abcam, ab64693            | 1:1,000       | Alexa Fluor 488 secondary |
| rabbit anti-CD32  | Abcam, ab155972           | 1:500         | TSA Alexa Fluor 488     |
| rabbit anti-CD163 | Abcam, ab182422           | 1:1,000       | TSA Alexa Fluor 488     |
| rabbit anti-L-Ferritin | Sigma Aldrich, F5012      | 1:2,000       | Alexa Fluor 488 secondary |

For qualitative MOI assessments, free-floating fluorescent immunohistochemistry was carried out on the 50- and 100-µm thick middle temporal gyrus sections as previously described. In short, sections were placed into tris–EDTA pH 9.0 buffer and microwaved at 1,100 W for 30 s or until the solution boiled. The sections were incubated in the solution containing primary antibodies for 72 h at 4°C on a rocking platform (Table 4) and then in a solution containing fluorophore-conjugated secondary antibody, specific to the primary antibody species, overnight at room temperature. Lastly, sections were incubated in Hoechst (1:20,000 in PBS, Molecular Probes, #33,342) mounted onto glass slides and coverslipped.

Lectin from Ulex europaeus-1 (UEA-1) was used for the visualisation of blood vessels as it is a specific marker of endothelial cells. Two forms of lectin from UEA-1 were used in conjunction with other primary antibodies to label blood vessels in the free-floating MTG sections. A biotinylated lectin from UEA-1 (1:1,000, Sigma-Aldrich, L8262) was visualised using an AlexaFluor 647-conjugated Streptavidin (1:500, Sigma-Aldrich, Cat. #709360).
S21374). Alternatively, a DyLight 594-conjugated lectin from UEA-1 (1:100, Vector Laboratories, DL-1067) was used to directly visualise endothelia.

For the quantification of MOIs co-labelling with HLA-DR, paraffin immunofluorescent staining was carried out on the 10-µm thick middle temporal gyrus sections as previously described. In short, following dewaxing, rehydration, antigen retrieval was carried out using tris-EDTA pH 9.0 buffer. Serum blocking was carried out and sections were subsequently incubated in the primary antibodies overnight at 4 °C and secondary antibodies for 4 h at RT. Finally, sections were incubated in Hoechst (1:20,000 in PBS, Molecular Probes, #33,342) for 10 min to stain all nuclei and coverslipped.

**Tyramide signal amplification.** A selection of primary antibodies required tyramide signal amplification (TSA) for visualisation as indicated in Table 2. TSA was carried out as previously described as well as the AlexaFluor conjugated secondary antibodies, specific to the non-amplified primary antibodies.

**Imaging.** For the visualisation of MOIs on Iba1-positive myeloid cells and assessment of MOI abundance on different microglial morphologies, goat-Iba1 was co-labelled with one MOI antibody in 50-µm thick free-floating middle temporal gyrus sections. For identification of MOI co-labelling with HLA-DR, goat anti-Iba1 and mouse anti-HLA-DR were co-labelled with one MOI antibody in 50-µm thick free-floating middle temporal gyrus sections. All sections were imaged on the Olympus FV1000 confocal microscope using the 100× oil immersion lens. Optical z-stacks were taken through the entirety of the cell body and processes. In the case of the microglial morphology assessments, morphologies were initially determined from the MOI staining, but also confirmed after imaging of both the MOI and Iba1. All images presented are focused maximum projections of confocal z-stacks of six to ten 1-µm thick optical slices.

To classify Iba1-positive cells as microglia or PVMs, goat anti-Iba1 was fluorescently co-labelled with lectin from UEA-1 in the 100-µm thick middle temporal gyrus sections. Microglia and PVMs were first classified based on previously described cell morphologies and their location relative to lectin-positive blood vessels: parenchymal microglia were identified in the tissue parenchyma and had small cell bodies with ramified processes, while PVMs were identified alongside lectin-positive blood vessels and had elongated cell bodies. The parenchymal microglia included juxtavascular microglia, which are microglia associated with blood vessels. This allowed for a more direct comparison between microglia and PVMs with relation to blood vessel structures and immunoreactivity of MOIs. Both microglia and PVMs were imaged on the Olympus FV1000 confocal microscope using the 100× oil immersion lens. Optical z-stacks at 1 µm intervals were taken through the entirety of the Iba1-positive cell body and its processes, as well as the entirety of the associated blood vessel. These optical z-stacks were presented as z-projections of the xy image to give a representation of the Iba1-positive cell and its adjacent vessel. Iba1 and UEA-1 were subsequently co-labelled with one MOI in 50-µm thick MTG sections to assess microglial and PVM expression of MOIs using the same imaging methods.

For the quantification of the abundance of MOIs co-labelled with HLA-DR, goat anti-Iba1 and mouse anti-HLA-DR were co-labelled with one MOI antibody in 10-µm thick paraffin-embedded MTG sections. Sections were imaged at 20× magnification on a Zeiss Z2 Axioimager using MetaSystems VSlide acquisition software and MetaCyte stitching software. Acquired images were opened on VSViewer v2.1.112 and images from two areas of grey matter (GM) and two areas of white matter (WM) were extracted.

**Manual counting and measurement of marker of interest abundance.** Manual counting was carried out in ImageJ v 1.5i. A region of interest (ROI) was drawn based on the Hoechst channel using the polygon selection tool. By selecting the counting ROI on the Hoechst channel, any bias towards areas of high or low co-labelling was removed. For the GM images, cortical layers I through VI were all included to exclude any layer bias. This ROI was approximately 1 mm² for WM images and 1.5 mm² for GM images. Prior to manual counting, five point measurements of background were measure in the Iba1, MOI, and HLA-DR images. All Iba1-positive microglia were subsequently counted within this ROI using the multipoint region tool on an Iba1-Hoechst image. Each point was placed on the cell body of an Iba1-positive cell with a Hoechst-positive nucleus and was therefore considered a coordinate where a microglia was found. Point intensities of Iba1, HLA-DR, and the MOI were measured as grey values between 0 and 255 at each coordinate. To be considered Iba1-positive, the Iba1 point intensity needed to be 20 grey values above background.

**Validation of point intensities as an accurate measure of Iba1, HLA-DR and MOI abundance in each cell.** To validate that the intensity of a single pixel within the Iba1-positive cell body was a sufficient measure of overall intensity, another 10 multipoint regions were placed randomly around the Iba1 cell body. The intensities of HLA-DR, CD74, or CD32 were subsequently measured at these 10 coordinates. The validation was carried out on approximately 30 Iba1-positive cells per case: a total of 148 cells were measured across the six cases. The mean point intensity measured across these 10 points were correlated with the original point intensity measured per Iba1-positive cell (Supplementary Fig. 1). The linear correlations were considered weak if \( r \leq 0.3 \), moderate if \( 0.3 < r \leq 0.8 \) and strong if \( r > 0.8 \), and statistical significance was set at \( p \leq 0.05 \)—the interpretation of the correlation values was used for all such correlations in this study.

For both cell membrane markers, the mean point intensity strongly correlated with the original measured PI (HLA-DR: \( r = 0.8601, p < 0.0001 \), Fig. 1A; CD32: \( r = 0.843, p < 0.0001 \), Fig. 1B). Alternatively, for the cytoplasmic marker, the measured point intensity only moderately correlated with the original measured PI (CD74: \( r = 0.7695, p < 0.0001 \), Fig. 1C) suggesting that single-pixel point intensity did not consistently reflect total cell intensity. For
this reason, the single point intensity method was used in combination with a second method (categorisation), on
the basis that a dual approach would strengthen the robustness of the conclusions. Therefore, multiple methods
were employed to quantify and statistically analyse the abundance of HLA-DR and MOIs, and the extent of their
co-labelling, in the Iba1-positive cell population.

**Statistical analysis of MOI abundance in the Iba1-positive cell population.** If a cell was Iba1-positive, it was sub-
sequently determined to be immunoreactive for HLA-DR or the MOI if the point intensities were 20 to 40 grey
values above background. This grey value threshold was determined from the counting images, and it allowed
for the detection of HLA-DR or MOI immunoreactivity within Iba1-positive cells and excluded autofluores-
cence present in the tissue. The mean percentages of Iba1-positive cells immunoreactive for HLA-DR or MOI
measured in each case in GM and WM were compared using paired t-tests. Each data point represents a case.
Statistical significance was set at p ≤ 0.05. These percentages were correlated with post-mortem delay and age
using a Spearman’s correlation. Male–female differences could not be investigated because of the low number of
cases in each group.

**Statistical analysis of HLA-DR and MOI co-labelling in the Iba1-positive cell population.** Due to
the variability in HLA-DR and MOI staining across Iba1-positive cell bodies, the statistical analysis of this
colabelling was carried out in two ways. Firstly, the point intensities of HLA-DR and MOI were linearly cor-
related. Secondly, The HLA-DR-MOI populations were categorised into HLA-DR(high/low) and MOI(high/low) and
the distribution of Iba1-positive cells into each population was analysed using a Chi-square analysis. The rationale
for categorisation was based on the identified limited of using single pixel point intensities: if single pixel point
intensity did not accurately reflect total cell intensity, binarization of the data would allow robust categorisation
of a cell as expressing each marker either at a high or low level.

**HLA-DR-MOI point intensity correlation analysis.** To determine whether the HLA-DR and MOI expression
was related, all Iba1-positive cells from all six normal cases were pooled and the HLA-DR and MOI point inten-
sities were correlated using a Pearson’s correlation. To determine whether HLA-DR and MOI expression were
related at higher levels of expression, the 10% of Iba1-positive cells with the highest HLA-DR point intensity or
MOI point intensity were correlated with their respective MOI point intensity or HLA-DR point intensity with
a Pearson’s correlation. While efforts were made to prevent overexposure of any pixels during imaging, some
saturated pixels of 255 grey values were measured for HLA-DR or MOI point intensities. To ensure these point
intensities did not skew any correlations carried out above, correlations were carried out with and without the
saturated pixels. No differences in correlation strength or statistical significance were observed (data not shown).

**Categorisation of HLA-DR-MOI populations and Chi-square analysis.** To quantify the extent of HLA-DR and
MOI co-labelling on microglia, Iba1-positive cells were categorised into HLA-DR(high/low) and MOI(high/low) groups
and the distribution of cells in each HLA-DR-MOI population was statistically analysed. Using the original
images, intensities for high versus low HLA-DR or MOI staining were compared to background staining. A
threshold intensity above background was subsequently determined for HLA-DR and each MOI. If a point
intensity for any given marker was higher than the threshold intensity above background, an Iba1-positive cell
was considered to have a high expression for this marker. Alternatively, if the point intensity was lower than the
threshold intensity above background, and Iba1-positive cell was considered to have a low expression. Therefore,
each Iba1-positive cell was classified as HLA-DR(high/low) and MOI(high/low), resulting in four HLA-DR-MOI groups;
HLA-DR(high) MOI(high), HLA-DR(high) MOI(low), HLA-DR(low) MOI(high), and HLA-DR(low) MOI(low).

HLA-DR and MOI co-labelling on Iba1 cells was first statistically assessed using a Chi-Square analysis. This
test determined whether the distribution of Iba1 cells in the HLA-DR(high) MOI(high), HLA-DR(high) MOI(low), HLA-
DR(low) MOI(high), and HLA-DR(low) MOI(low) groups was due to chance. Put simply, this test determined whether there was
a relationship between HLA-DR expression and MOI expression. Statistical significance was set at p ≤ 0.05.
Data presented are from the tests on pooled Iba1-positive cells from all cases. However, the distribution of HLA-
DR-MOI populations in each case was also investigated and the same distributions and statistical significances
were observed (data not shown).

To determine whether activated Iba1-positive cells were more likely to express MOIs, Iba1-positive cells
from each normal case were grouped into HLA-DR(high) or HLA-DR(low) populations and the percentage of these
populations found to be MOI(high) was compared. To determine whether MOI(high) Iba1-positive cells were more
activated, Iba1-positive cells were grouped into MOI(high) or MOI(low) populations, and the percentage of these
populations found to be HLA-DR(high) was compared. Because all data were equally distributed with no difference
in variances, data were compared using an unpaired student’s t-test and statistical significance was set at p ≤ 0.05.

**Ethics approval and consent to participate.** Ethics approval was obtained through the University of
Auckland Human Participants Ethics committee (protocol number 011654).

**Consent for publication.** Not applicable.

**Availability of data and materials** Not applicable.
References

1. Ransohoff, R. M. A polarizing question: do M1 and M2 microglia exist. *Nat. Neurosci.* 19, 987–991 (2016).
2. Haynes, S. E. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. *Nat. Neurosci.* 9, 1512–1519 (2006).
3. Butovsky, O. et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. *Nat. Neurosci.* 17, 131–143 (2014).
4. Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer’s disease. *Cell* 169, 1276–1290 (2017).
5. Moore, C. S. et al. P2Y12 expression and function in alternatively activated human microglia. *Neutrol. Immunomunol. Neurinflam. 2*, e80 (2015).
6. Walker, D. G. et al. Patterns of expression of purinergic receptor P2RYY12, a putative marker for non-activated microglia, in aged and Alzheimer’s disease brains. *Int. J. Mol. Sci.* 21, 678 (2020).
7. Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. *Nature* 570, 332–337 (2019).
8. Bennett, M. L. et al. New tools for studying microglia in the mouse and human CNS. *Proc. Natl. Acad. Sci. USA* 113, E1738–E1746 (2016).
9. Satoh, J. I. TMEM119 marks a subset of microglia in the human brain. *Neuropathology* 36, 39–49 (2016).
10. Becker-Herman, S., Arie, G., Medvedovsky, H., Kerem, A. & Shachar, I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. *Mol. Biol. Cell* 16, 5061–5069 (2005).
11. Stumptner-Cuvelette, P. & Benaroch, P. Multiple roles of the invariant chain in MHC class II function. *Biochim. Biophys. Acta 1542, 1–13* (2002).
12. Bryan, K. J. et al. Expression of CD74 is increased in neurofibrillary tangles in Alzheimer’s disease. *Mol. Neurodegener.* 3, 8 (2008).
13. Linehan, M. P., Martinez-Pomares, I. & Gordon, S. Mannose receptor and scavenger receptor: two macrophage pattern recognition receptors with diverse functions in tissue homeostasis and host defense. *Biol. Pathol. Innate Immun. Mech. 479, 1–14* (2000).
14. Faraco, G., Park, L., Anrather, J. & Iadecola, C. Brain perivasculary macrophages: characterization and functional roles in health and disease. *J. Mol. Med. 95*, 1143–1152 (2017).
15. Holder, G. E. et al. Expression of the mannose receptor CD206 in HIV and SIV encephalitis: a phenotypic switch of brain perivasculary macrophages with virus infection. *J. Neuroimmunopharmacol.* 9, 716–726 (2014).
16. Galja, I. et al. Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. *Glia* 49, 375–384 (2005).
17. Anania, J. C., Chenoweth, A. M., Wines, B. D. & MarkHogarth, P. The human FcYRII (CD32) family of leukocyte FCR in health and disease. *Front. Immunol.* 10, 1–17 (2019).
18. Peress, N. S., Fleit, H. B., Perillo, E., Kuljis, R. & Pezzullo, C. Identification of Fc gamma RII, II and III on normal human brain ramified microglia and on microglia in senile plaques in Alzheimer’s disease. *J. Immunol. 48*, 71–79 (1993).
19. Eterodot, A. & Moestup, S. K. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. *Antioxid. Redox Signal. 18*, 2352–2363 (2013).
20. Fabriek, B. O. et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. *Glia 51*, 297–305 (2005).
21. Kim, W. K. et al. CD163 identifies perivascular macrophages in normal and viral encephalitides and potential precursors to perivascular macrophages in blood. *Am. J. Pathol. 168*, 822–834 (2006).
22. Pey, P., Pearce, R. K., Kalaitzakis, M. E., Griffin, W. S. T. & Gentleman, S. M. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease. *Acta Neuropathol. Commun.* 2, 21 (2014).
23. Roberts, E. S., Masliah, E. & Fox, H. S. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). *J. Neuropathol. Exp. Neurol. 63*, 1255–1264 (2004).
24. Borda, J. T. et al. CD163, a marker of perivascular macrophages, is up-regulated by microglia in simian immunodeficiency virus encephalitis after haptoglobin-hemoglobin complex stimulation and is suggestive of breakdown of the blood-brain barrier. *Am. J. Pathol. 172*, 725–737 (2008).
25. Lopes, K. O., Sparks, D. L. & Streit, W. J. Microglial dystrophy in the aged and Alzheimer’s disease brain is associated with ferritin immunoreactivity. *Glia 56*, 1048–1060 (2008).
26. Streit, W. J., Braak, H., Xue, Q. & Bechmann, I. Dysrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely prede neurodegeneration in Alzheimer’s disease. *Acta Neuropathol. 118*, 475–485 (2009).
27. Singh-Bains, M. K. et al. Altered microglia and neurovasculature in the Alzheimer’s disease cerebellum. *Neurobiol. Dis.* 132, 104589 (2019).
28. Bretschneider, J. et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. *Acta Neuropathol. 123*, 395–407 (2012).
29. Hopperton, K. E. K., Mohammad, D., Trépanier, M. O. M., Giuliano, V. & Bazinet, R. P. Markers of microglia in postmortem brain samples from patients with Alzheimer’s Disease: a systematic review. *Mol. Psychiatry* https://doi.org/10.1038/mp.2017.246 (2017).
30. Walker, D. G. & Lue, L.-F. Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains. *Alzheimers. Res. Ther.* 7, 56 (2015).
31. McGeer, P. L., Itagaki, S., Tago, H. & McGeer, E. G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci. Lett.* 79, 195–200 (1987).
32. Gehrmann, J., Banati, R. B. & Kreutzberg, G. W. Microglia in the immune surveillance of the brain: human microglia constitutively express HLA-DR molecules. *J. Neurosci.* 48, 189–198 (1993).
33. Haynes, W. J., Xue, Q.-S., Tischer, J. & Bechmann, I. Microglial pathology. *Acta Neuropathol. Commun.* 2, 142 (2014).
34. Stence, N., Waite, M. & Dailey, M. E. Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. *Glia* 33, 256–266 (2001).
35. Sierra, A. et al. Microglia shape adult hippocampal neurogenesis through apoptosis-coupled phagocytosis. *Cell Stem Cell* 7, 483–495 (2010).
36. Sierra, A., Abiega, O., Shahraz, A. & Neumann, H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. *Front. Cell. Neurosci.* 7, 1–12 (2013).
37. Peri, F. & Nüsslein-Volhard, C. Live imaging of neuronal degradation by microglia reveals a role for v0-ATPase a1 in phagosomal fusion in vivo. *Cell 133*, 916–927 (2008).
38. Bachstetter, A. D. et al. Disease-related microglia heterogeneity in the hippocampus of Alzheimer’s disease, dementia with Lewy bodies, and hippocampal sclerosis of aging. *Acta Neuropathol. Commun.* 3, 1–16 (2015).
39. Streit, W. J. & Xue, Q. S. Life and death of microglia. *J. Neuroimmunopharmacol.* 4, 371–379 (2009).
40. Bachstetter, A. D. et al. Rod-shaped microglia morphology is associated with aging in 2 human autopsy series. *Neurobiol. Aging 52*, 98–105 (2017).
The authors declare no competing interests.

Acknowledgements

We would like to acknowledge Marika Eszes at the Centre for Brain Research (the University of Auckland, New Zealand) for her technical role in the Neurological Foundation of New Zealand’s Human Brain Bank and the imaging team at the Biomedical Imaging Research Unit (the University of Auckland, New Zealand). MEVS is supported by the Neurological Foundation of New Zealand (W & B Miller scholarship), Brain Research New Zealand, and the University of Auckland. HCM is supported by the Health Education Trust and Brain Research New Zealand. BR is supported by the Auckland Medical Research Foundation and the Health Research Council of New Zealand. This work was also supported by a programme grant from the Health Research Council of New Zealand. BR is supported by the Auckland Medical Research Foundation and the Health Research Council of New Zealand. MEVS is supported by the Neurological Foundation of New Zealand (W & B Miller scholarship). Brain Research New Zealand, and the University of Auckland. HCM is supported by the Health Education Trust and Brain Research New Zealand. BR is supported by the Auckland Medical Research Foundation and the Health Research Council of New Zealand. This work was also supported by a programme grant from the Health Research Council of New Zealand. The Neurological Foundation of New Zealand supported the Human Brain Bank.

Author contributions

MEVS, B.R., M.D. and M.A.C. conceptualized the study. R.I.M.F. and M.A.C. collected and processed the human tissue. MEVS carried out the experimental procedures, with assistance from H.C.M. and B.R. M.E.V.S. carried out all quantification. Data analysis and interpretation were carried out by M.E.V.S and B.R. Manuscript was prepared by M.E.V.S, and H.C.M., M.A.C., M.D. and B.R. carried out the critical revisions. MD and MAC supervised the study. All authors read and approved of the final manuscript.

Competing interests

The authors declare no competing interests.
